SEC Form 4 · accession 0001179110-18-002291
Allergan plc · AGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William Meury
Officer — Chief Commercial Officer
Period of report
Feb 14, 2018
Accepted (ET)
Feb 16, 2018 · 5:10 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001578845
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares, par value $0.0001F1,F2 | Feb 14, 2018 | M | 1,957 | $51.07 | A | 56,944 | D | |
| Ordinary Shares, par value $0.0001F2 | Feb 14, 2018 | M | 2,765 | $51.07 | A | 59,709 | D | |
| Ordinary Shares, par value $0.0001F2 | Feb 14, 2018 | M | 1,510 | $66.20 | A | 61,219 | D | |
| Ordinary Shares, par value $0.0001F2 | Feb 14, 2018 | M | 17,381 | $66.20 | A | 78,600 | D | |
| Ordinary Shares, par value $0.0001F3,F2 | Feb 14, 2018 | S | 25,079 | $157.18 | D | 53,521 | D | |
| Ordinary Shares, par value $0.0001F4,F2 | Feb 14, 2018 | S | 1,200 | $157.60 | D | 52,321 | D | |
| Ordinary Shares, par vaule $0.0001F5,F2 | Feb 14, 2018 | S | 1,700 | $158.78 | D | 50,621 | D | |
| Ordinary Shares, par value $0.0001F6,F2 | Feb 14, 2018 | S | 2,400 | $159.82 | D | 48,221 | D | |
| Ordinary Shares, par vaule $0.0001F7,F2 | Feb 14, 2018 | S | 1,000 | $161.10 | D | 47,221 | D | |
| Ordinary Shares, par value $0.0001F8,F2 | Feb 14, 2018 | S | 4,700 | $162.22 | D | 42,521 | D | |
| Ordinary Shares, par value $0.0001F9,F2 | Feb 14, 2018 | S | 7,200 | $163.04 | D | 35,321 | D | |
| Ordinary Shares, par value $0.0001F10,F2 | Feb 14, 2018 | S | 2,000 | $164.62 | D | 33,321 | D | |
| Ordinary Shares, par value $0.0001F11,F2 | Feb 14, 2018 | S | 13,600 | $165.16 | D | 19,721 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock OptionF12 | $51.07 | Feb 14, 2018 | M | 1,957 | D | — | Dec 7, 2018 | Ordinary Shares | 1,957 | 0 | D |
| Non-Qualified Options to Purchase Common StockF13 | $51.07 | Feb 14, 2018 | M | 2,765 | D | — | Dec 7, 2018 | Ordinary Shares | 2,765 | 0 | D |
| Incentive Stock OptionF14 | $66.20 | Feb 14, 2018 | M | 1,510 | D | — | Dec 6, 2019 | Ordinary Shares | 1,510 | 0 | D |
| Non-Qualified Options to Purchase Common StockF15 | $66.20 | Feb 14, 2018 | M | 17,381 | D | — | Dec 6, 2019 | Ordinary Shares | 17,381 | 0 | D |
Explanation of responses
- F1The total number of shares reported has been reduced by 423 due to prior inadvertent over-reporting of shares beneficially owned by the Reporting Person.
- F10The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $164.04 to $165.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- F11The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $165.05 to $165.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- F12The option vested on December 8, 2013.
- F13The option vested in five equal installments on December 8, 2009, 2010, 2011, 2012 and 2013.
- F14The option vested on December 7, 2014.
- F15The option vested in five equal installments on December 7, 2010, 2011, 2012, 2013 and 2014.
- F2Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.
- F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $156.29 to $157.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- F4The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $157.30 to $158.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- F5The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $158.30 to $159.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- F6The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $159.41 to $160.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- F7The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $160.59 to $161.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- F8The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $161.67 to $162.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- F9The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $162.68 to $163.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.